Table 3.
Logistic regression analysis of association between factors at Week 52 (CZP discontinuation) and clinical outcomes at Week 104 in patients who were treated with CZP + MTX in Year 1 and entered the post‐treatment period (CZP + MTX→MTX, n = 108)
|
SDAI remission odds ratio (95% CI) P value |
||
|---|---|---|
| Univariate | Multiple | |
| DAS28‐ESR |
0.29 (0.16‐0.54) <.001 |
0.29 (0.16‐0.54) <.001 |
| HAQ‐DI |
0.47 (0.11‐2.03) .309 |
|
| mTSS |
0.85 (0.57‐1.26) .408 |
|
| RF |
0.69 (0.50‐0.95) .022 |
0.67 (0.47‐0.96) .028 |
| Anti‐CCP antibody |
0.86 (0.63‐1.19) .370 |
|
| MMP‐3 |
0.77 (0.35‐1.70) .516 |
|
Abbreviations: CCP, cyclic citrullinated peptide; CZP, certolizumab pegol; DAS28‐ESR, Disease Activity Score of 28 joints ‐ erythrocyte sedimentation rate; HAQ‐DI, Health Assessment Questionnaire Disability Index; MMP‐3, matrix metalloproteinase; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; RF, rheumatoid factor; SDAI, simple disease activity index.